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NICE has accredited the process used by the British Association of 
Dermatologists to produce clinical guidelines. The renewed accreditation is valid 
until 31 May 2021 and applies to guidance produced using the process 
described in Updated guidance for writing a British Association of Dermatologists 
clinical guidance – the adoption of the GRADE methodology 2016. The original 
accreditation term began on 12 May 2010. More information on accreditation can 
be viewed at www.nice.org.uk/accreditation. 
1.0 PURPOSE AND SCOPE 
The overall objective of the guideline is to provide up-to-date, evidence-based 
recommendations for the management of hidradenitis suppurativa (HS). The document aims 
to:  
• offer an appraisal of all relevant literature up to July 2018, focusing on any key 
developments 
• address important, practical clinical questions relating to the primary guideline 
objective.  
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• provide guideline recommendations and if appropriate research recommendations 
 
The guideline is presented as a detailed review with highlighted recommendations for 
practical use in primary care and secondary care, in addition to an updated Patient 
Information Leaflet (PIL; available on the BAD website, www.bad.org.uk/leaflets). 
 
1.1 Exclusions 
This guideline does not cover management of the non-HS elements of syndromes such as 
PASH (pyoderma gangrenosum, acne, and hidradenitis suppurativa) and PAPASH 
(pyoderma gangrenosum, acne, psoriasis, arthritis and suppurative hidradenitis). Nearly all 
the evidence underpinning the guideline relates to studies in adults. The guideline 
development group (GDG) is mindful that HS onset is often before adulthood and 
interventions used for adults with HS are quite often considered for young people and 
children. Given the paucity of high-quality evidence relating to HS in those younger than 18 
years, with the exception of adalimumab being licensed for people with HS aged 12 years 
and above, specific recommendations about treatment in young people and children could 
not be included at the current time.  
 
2.0 METHODOLOGY 
This set of guidelines has been developed using the BAD’s recommended methodology1 
(see further information in Appendix J) with reference to the Appraisal of Guidelines 
Research and Evaluation (AGREE II) instrument [www.agreetrust.org]2 and the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE).3 
Recommendations were developed for implementation in the UK National Health Service 
(NHS).  
 
The GDG, which consisted of consultant dermatologists, a consultant plastic surgeon, a 
general practitioner, a dermatology registrar, a clinical nurse specialist, patient 
representatives and a technical team (consisting of a guideline research fellow and project 
manager providing methodological and technical support), established several clinical 
questions pertinent to the scope of the guideline and a set of outcome measures of 
importance to patients, ranked according to the GRADE methodology (see section 3.0). 
 
A systematic literature search of PubMed, MEDLINE, EMBASE, Cochrane and AMED 
databases was conducted by the technical team to identify key articles for hidradenitis 
suppurativa up to July 2018; search terms and strategies are detailed in the supplementary 
information (Appendix K). Additional references relevant to the topic were also isolated from 
citations in reviewed literature. Data extraction and critical appraisal were carried out by two 
clinicians and checked by the technical team. Data synthesis, evidence summaries, lists of 
excluded studies and the PRISMA diagram were prepared by the technical team. Evidence 
from included studies was rated according to the GRADE system (high, moderate, low or 
very low quality). Recommendations are based on evidence drawn from systematic reviews 
of the literature pertaining to the clinical questions identified, following discussions with the 
entire GDG and factoring in all four factors that would affect its strength rating according to 
the GRADE approach (i.e. balance between desirable and desirable effects, quality of 
evidence, patient values and preferences and resource allocation). All GDG members 
contributed towards drafting and/or reviewing the narratives and information in the guideline 
and supporting information documents. When there is insufficient evidence from the 
3 
literature, informal consensus is reached based on the experience of the GDG. The 
summary of findings with forest plots (Appendix D), GRADE evidence profiles indicating the 
quality of evidence (Appendix E), clinical evidence summary (Appendix B), summary of 
included comparative studies (Appendix F), narrative findings tables for non-comparative 
studies (Appendix G), tables Linking the Evidence To the Recommendations (LETR, 
Appendix C), PRISMA flow diagram (Appendix H) and lists of excluded studies (Appendix I) 
are detailed in the supporting information. The strength of recommendation is expressed by 
the wording and symbols as shown in Table 1.  
Strength Wording Symbols Definition 
Strong 
recommendation for 
the use of an 
intervention 
“Offer” 





Benefits of the intervention outweigh 
the risks; most patients would choose 
the intervention whilst only a small 
proportion would not; for clinicians, 
most of their patients would receive the 
intervention; for policy makers, it would 
be a useful performance indicator. 
Weak 
recommendation for 
the use of an 
intervention 
“Consider”  
Risks and benefits of the intervention 
are finely balanced; most patients 
would choose the intervention, but 
many would not; clinicians would need 
to consider the pros and cons for the 
patient in the context of the evidence; 
for policy makers, it would be a poor 
performance indicator where variability 
in practice is expected. 
No recommendation Θ 




against the use of 
an intervention 
“Do not offer”  
Risks of the intervention outweigh the 
benefits; most patients would not 
choose the intervention whilst only a 
small proportion would; for clinicians, 
most of their patients would not receive 
the intervention. 
Table 1. Strength of recommendation ratings 
 
3.0 INTRODUCTION 
There is currently a paucity of effective treatment options for HS, but common medical 
therapy approaches include antiseptic washes, steroid injections, topical and oral antibiotics 
(single agents or combination treatment), retinoids, dapsone, oral contraceptive agents, oral 
immunomodulators, and anti-TNF therapy. Surgical procedures range from incision and 
drainage for acute flares, narrow margin excision and extensive excision with closure by 
secondary intention, skin flap or graft. Other treatment options include radiotherapy, 
psoralen and UVA (PUVA) phototherapy, photodynamic therapy and laser therapy.  
 
3.1 Clinical questions and outcomes  
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Management strategies in HS are highly variable and are currently undertaken by both 
generalists and specialists spanning emergency medicine, internal medicine, dermatology, 
plastic surgery, urology, gynaecology and general surgery. To address these matters the 
GDG established several clinical questions pertinent to the scope of the guideline. 
 
In people with hidradenitis suppurativa: 
1. What is the efficacy and safety of medical interventions? 
• topical  
• conventional systemic  
• biologic  
• laser and light 
• other therapies 
2. What is the efficacy and safety of surgical interventions? 
3. What are the self-management options and the evidence to support them? 
 
The GDG also established two sets of outcome measures of importance to patients (see 
Table 2), one for medical interventions and another for surgery; these were ranked 
according to the GRADE methodology4 by patient/carer representatives, data on which are 
extracted from included studies (see Appendix F). Outcomes ranked 7, 8 and 9 are critical 
for decision-making; those ranked 4, 5 and 6 are important but not critical for decision 
making: 
 
Medical interventions Surgical interventions 
Quality of Life (QoL)  
Adverse effects – serious 
Pain  
Disease-specific physician score  
Physician’s global assessment (PGA) 
Patient’s global self-assessment 










Overall satisfaction  
Functional (arm abduction)  
Complication rates  
Cosmetic 
Duration of hospitalization 









Table 2. Outcome measures of importance to patients for medical and surgical interventions 
 
4.0 SUMMARY OF RECOMMENDATIONS 
The following recommendations and ratings were agreed upon unanimously by the core 
members of the GDG and patient/carer representatives. For further information on the 
wording used for recommendations and strength of recommendation ratings see Table 1. 
The evidence for recommendations is based on the studies as listed. GDG 
recommendations relating to referral pathways are based on discussion and clinical 
experience, as evidence-based details are not available at the time of writing. The GDG is 
aware of the lack of high-quality evidence for some of these recommendations, therefore 
strong recommendations with an asterisk (*) are based on available evidence, as well as 
consensus and specialist experience. Good practice point (GPP) recommendations are 
derived from informal consensus. 
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R1 (GPP) Manage people with HS via a multi-disciplinary team approach, particularly when 
considering surgical interventions 
 
R2 (GPP) In all people with HS, document the Hurley stage at baseline for the worst-affected 
region. For Hurley stage III (severe) disease consider immediate referral to dermatology 
secondary care.  
 
R3 (GPP) Provide a patient information leaflet (www.bad.org.uk/leaflets) to all people with 
HS, treat pain if needed and provide dressings for pus-producing lesions 
 
R4 (GPP) Screen people with HS for associated co-morbidities including depression, anxiety 
and cardiovascular risk factors (diabetes, hypertension, hyperlipidaemia and central obesity). 
If persistent gastrointestinal symptoms are reported refer for inflammatory bowel disease 
screening.   
 
R5 (GPP) Where relevant, refer people with HS to smoking-cessation services  
 
R6 (GPP) Where relevant, refer people with HS to weight-management services  
 
R7 (GPP) Measure treatment response in people with HS using recognized instruments for 
pain and quality of life, including an inflammatory lesion count for those on adalimumab 
therapy 
 
R8 (GPP) In people with long-standing, moderate-to-severe HS, monitor for fistulating 
gastrointestinal disease, inflammatory arthritis, genital lymphoedema, cutaneous squamous 
cell carcinoma, and also for anaemia  
 
R9 () Offer* oral tetracyclines such as doxycycline or lymecycline for at least 12 weeks to 
people with HS, considering treatment breaks to assess need for ongoing therapy and to 
limit the risk of antimicrobial resistance 
 
R10 () Offer* combination treatment with oral clindamycin 300 mg twice daily and 
rifampicin 300 mg twice daily for 10 to 12 weeks to people with HS who are unresponsive to 
oral tetracyclines  
 
R11 () Consider acitretin 0.3-0.5 mg/kg/day in males and non-fertile females with HS who 
are unresponsive to antibiotic therapies  
 
R12 () Consider dapsone in people with HS who are unresponsive to antibiotic therapies  
 
R13 () Offer* adalimumab1 40 mg weekly to people with moderate-to-severe HS that is 
unresponsive to conventional systemic therapy 
 
R14 () Consider infliximab 5 mg/kg every 8 weeks in people with moderate-to-severe HS 
that is unresponsive to adalimumab therapy 
 
 
1 Licensed for children and young people aged 12 to 17 years, and adults 
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R15 () Consider clindamycin 1% solution in people with HS 
 
R16 () Consider intralesional corticosteroid injections for carefully selected, individual HS 
lesions during the acute phase  
 
R17 (GPP) Consider metformin in people with HS with concomitant diabetes mellitus, and 
females with HS and polycystic ovary syndrome or pregnancy 
 
R18 () Consider extensive excision in people with HS to minimise recurrence rate  
 
R19 () Consider extensive excision for people with HS when conventional systemic 
treatments have failed 
 
R20 () Consider secondary intention healing (or TDAP flap closure for axillary wounds) in 
people with HS following extensive excision 
 
R21 () Do not offer* isotretinoin to people with HS unless there are concomitant 
moderate-to-severe acneiform lesions of the face or trunk 
 
R22 () Do not offer* adalimumab 40 mg every other week to people with moderate-to-
severe HS that is unresponsive to conventional systemic therapy 
 
R23 () Do not offer* etanercept to people with moderate-to-severe HS that is 
unresponsive to conventional systemic therapy 
 
R24 () Do not offer* cryotherapy to people with HS to treat lesions during the acute 
phase due to pain from the procedure 
 
R25 () Do not offer* microwave ablation to people with HS 
 
Insufficient evidence to support any recommendation 
 
Θ Currently, there is insufficient evidence to recommend alitretinoin, anakinra, apremilast, 
atorvastatin, azathioprine, ciclosporin, colchicine, cyproterone, ethinyloestradiol with 
cyproterone acetate, ethinyloestradiol with norgestrel, finasteride, fumaric acid esters, 
hydrocortisone, hyperbaric oxygen therapy, intravenous antibiotics, isoniazid, laser and 
photodynamic therapies, MABp1 (anti-IL-1 therapy), methotrexate, oral prednisolone, oral 
zinc, phototherapy, photochemotherapy, radiotherapy, secukinumab, spironolactone, 
staphage lysate, tolmetin sodium and ustekinumab for people with HS that is unresponsive 
to conventional systemic therapy 
 
List of key future research recommendations (FRRs) 
 
FRR1 A prospective RCT evaluating the alignment/role of biologic therapy with surgical 




FRR2 A prospective RCT evaluating the efficacy and safety of anakinra in people with 
(moderate-to-severe?) HS (that is unresponsive to conventional systemic therapy)  
 
FRR3 A prospective RCT evaluating the efficacy and safety of ustekinumab in people with 
(moderate-to-severe?) HS (that is unresponsive to conventional systemic therapy) 
 
FRR4 A prospective RCT evaluating the efficacy and safety of secukinumab in people with 
(moderate-to-severe) HS (that is unresponsive to conventional systemic therapy) 
 
FRR5 A registry of people with HS receiving systemic therapy, including biologic therapy, to 
determine the long-term safety and efficacy of these interventions 
 
FRR6 A prospective RCT evaluating the relative efficacy and tolerability of topical antiseptics 
and topical antibiotics for mild HS 
 
FRR7 A prospective RCT evaluating the efficacy and safety of laser and light therapies in 
people with HS. Trials adopting a within-participant design should incorporate a sham 
intervention where possible, with matched left/right anatomical sites, and report all results 
fully (i.e. number of participants with i) positive outcomes for both interventions, ii) positive 
outcomes for only one intervention (reported separately for each intervention) and iii) 
negative outcomes for both interventions) 
 
FRR8 A larger, prospective RCT evaluating the dosing, efficacy and safety of oral 
tetracyclines in HS 
 
FRR9 A prospective RCT evaluating the efficacy, duration of treatment and safety of oral 
clindamycin and rifampicin in people with HS 
 
FRR10 A prospective RCT evaluating the efficacy and safety of oral retinoids in people with 
HS 
 
FRR11 A prospective RCT evaluating the efficacy and safety of dapsone in people with HS 
 
FRR12 A prospective RCT investigating the management of acute flares, including 
intralesional triamcinolone injections 
 
FRR13 A prospective RCT evaluating lifestyle modifications, such as smoking cessation and 
weight loss, on HS severity 
 
FRR14 A long-term pharmacovigilance study (open registry) for systemic therapy including 
biologic therapy 
 
FRR15 Studies on stratification of treatment response (personalised medicine) – phenotype, 
genotype, biomarkers, pK studies 
 




FRR17 A prospective RCT investigating endocrine therapies in people with HS 
 
FRR18 A prospective RCT of extensive excision of axillary HS (Hurley stages II and III) with 
closure using TDAP flaps vs. secondary intention closure (possibility of within-participant, 
bilateral studies)  
 
FRR19 A prospective RCT of continued optimal non-surgical therapy with extensive surgical 
excision of a single site for comparative evaluation of outcome between operated site and 
contralateral non-operated axilla or groin 
 
FRR20 A prospective head-to-head RCT of deroofing vs. best medical intervention  
 
FRR21 A long-term study looking at recurrence and complication rates following surgery 
 
FRR22 A prospective RCT of extensive excision of axillary HS compared with narrow margin 
excision of active lesions (possibility of within-participant, bilateral studies) 
    
5.0 ALGORITHM 
The recommendations and discussions in the LETR (see Appendix C in the supplementary 
information) and consensus specialist experience were used to produce the management 
pathway for people with HS (Figure 1). 
 
(see separate JPEG 600 dpi file) 
 
Figure 1. Management pathway for people with HS. *Licensed in those aged 12 years and 
above. **Surgical interventions are relatively under-represented in the management pathway 
because evidence of high quality, in the form of randomised controlled trials, is sparse.  
 
6.0 BACKGROUND  
6.1 Definition  
Hidradenitis suppurativa (HS) is defined as a “chronic, inflammatory, recurrent, debilitating, 
skin follicular disease that usually presents after puberty with painful deep seated, inflamed 
lesions in the apocrine gland-bearing areas of the body, most commonly, the axillary, 
inguinal and anogenital regions”.5,6 
 
6.2 Epidemiology 
Prevalence has been estimated at approximately 1-4% in the U.K. population7 and the 
typical age of onset is in the second to fourth decades of life.8-10 There is a female 
predominance (3:1, F:M) and an association with obesity and smoking, with odds ratios of 
3.3 and 3.6, respectively, compared with controls.7 However, non-smoking patients of 
normal BMI are seen in clinical practice. A population-based study from the USA found that 
HS prevalence among African American and biracial individuals was 3-fold and 2-fold 
greater, respectively, than the prevalence in white individuals.11 There is a nearly doubled 
risk of cardiovascular-associated death in HS patients compared with controls,12 in keeping 
with high rates of smoking and also associations with type 2 diabetes, hyperlipidaemia and 
hypertension.7 HS is associated with pilonidal sinus, which may be a phenotypic variant, as 
well as acne vulgaris7 People with HS have a higher risk of depression7,13 and completed 
suicide 14 which may relate to HS being a chronic, painful disease with a large impact on 
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quality of life. There is an association between HS and Crohn’s disease but not with 
ulcerative colitis.7,15 
 
6.3 Clinical presentation 
HS may present with comedones (characteristically paired), papules, pustules, nodules, 
cysts, abscesses, sinus tracts and fistulae in flexural areas however there is significant 
phenotypic variation amongst patients.16 The condition can cause severe pain, as well as 
pruritus, chronic discharge (serous, purulent or blood-stained) and a persistent malodour. 
Longstanding disease can result in fibrosis, dermal contractures, scarring and a consequent 
reduction in mobility. The disease targets flexural areas, notably the axillae, groin, perineum, 
buttocks, medial thighs, sub-mammary region, abdominal fold and posterior auricular region. 
Disease complications include fistula formation (affecting the urethra, bladder or rectum), 
lymphoedema, anaemia and the development of squamous cell carcinoma (SCC).17  
 
The associated pain, chronic purulent discharge, persistent malodour and the involvement of 
intimate sites in HS can result in significant patient morbidity. A survey of 114 patients 
referred to secondary care revealed an average Dermatology Life Quality Index (DLQI) 
score of 8.9,18 demonstrating a moderate effect on quality of life. HS can have far reaching 
social and economic consequences, affecting sexual health,19 relationships and 
employment. 
 
6.4 Diagnostic criteria and measures of disease severity 
Consensus diagnostic criteria state that individuals require typical lesions (painful nodules, 
abscesses, sinus tracts, bridged scars or open comedones) in typical sites (axillae, groin, 
perineal region, perianal region, infra and inter mammary folds or buttocks) and that the 
disease must be chronic and recurrent.20 Baseline disease severity in each skin region is 
often measured using the Hurley staging system (Table 3).21 The Hurley system is relatively 
insensitive to change, and so other instruments are used to measure the efficacy of 
treatment. Patient-reported domains include pain, measured with a visual analogue scale or 
numeric rating scale (0-10) and quality of life, measured with a dermatology-specific scale 
such as the dermatology life quality index (DLQI)22 or Skindex.23 Several physician-reported 
instruments are available in the literature including Sartorius score;24 however, most have 
not undergone robust validation.25 More recently, HiSCR has been developed as an 
endpoint for clinical trials, defined as a 50% reduction from baseline in inflammatory nodules 
and abscesses, with no increase in abscesses or draining sinuses.26 In approving 
adalimumab for moderate-to-severe HS, NICE used a modified version of the HiSCR 
endpoint, stipulating that a 25% reduction in inflammatory nodules and abscesses is 
required to continue therapy.27 
 
Stage 




Isolated lesions with no sinus tract formation and minimal or 
no scarring 
II Moderate 
Recurrent lesions separated by normal skin with sinus tract 
formation and scarring 
III Severe Multiple lesions coalescing into inflammatory plaques 
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involving most of the affected region 
Table 3. Hurley staging system for baseline disease severity in each skin region 
 
6.5 Dermatopathology 
HS is a clinical diagnosis and histopathological confirmation is rarely needed. Common 
histopathological features include follicular hyperkeratosis, follicular hyperplasia and follicular 
occlusion with an associated spongiform infundibulofolliculitis.28 These changes may be 
associated with follicular dilatation, follicular rupture and the formation of keratin containing 
cysts (lined by stratified squamous epithelium), abscesses, sinus tracts, granulomas, fibrosis 
and scarring. 
 
6.6 Disease pathogenesis 
The pathogenesis of HS remains poorly understood. Histopathological studies suggest that 
HS is primarily a disease of follicular occlusion.28 Up to 42% of HS patients report a family 
history of the condition and it can follow autosomal dominant inheritance in some 
kindreds.29,30 Recent genetic studies revealed that heterozygous mutations in the gamma-
secretase genes NCTSN, PSEN1 and PSENEN underlie a few familial cases of HS.31,32 
These would appear to tie in with the above histopathological studies in so far as alterations 
in gamma-secretase gene expression in animal models can result in follicular occlusion.33  
 
The significant inflammatory response seen in HS has led some to speculate that it may be a 
disease of aberrant immunity and it is noteworthy that immunomodulatory treatments 
including anti-TNF agents can be of benefit.34 The female predominance, post-pubertal 
onset, pre-menstrual flares and clinical improvement often observed during pregnancy imply 
a role for hormones in HS however the mechanism remains unknown.35 The role of bacteria 
in exacerbations is uncertain, for example short courses of antibiotics do not seem to alter 
natural history of a flare.10 Antibiotics may confer a benefit via their anti-inflammatory 
properties rather than any bactericidal or bacteriostatic effects. Obesity may have an impact 
on HS by mechanically increasing friction at flexural sites (thus potentially damaging 
follicular outlets), increasing sweat retention or increasing the circulating level of pro-
inflammatory cytokines (for example, IL-1β and TNF-α are both secreted by macrophages 
within visceral fat).36,37 The exact mechanisms by which smoking contributes to disease 
pathogenesis remain unclear however nicotine has been shown to induce epidermal 
hyperplasia and follicular plugging.38  
 
7.0 SELF-MANAGEMENT 
What can a person with HS do to help manage their condition? In most areas, evidence is 
weak or absent, however, a list of suggestions is provided below following feedback from 
patient/carer representatives on the GDG: 
• Obtain up-to-date information about HS from the BAD’s Patient Information Leaflet 
web page (www.bad.org.uk/leaflets). 
• Consider joining a patient support group, such as the HS Trust in the U.K. 
(www.hstrust.org). Mutual support is available via associated social media groups. 
• Obtain adequate pain relief from your General Practitioner (GP) to help manage the 
pain associated with HS flares or chronically active disease. 
• Avoid tight clothing and synthetic materials that can increase friction and may 
contribute to flares. 
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• Obtain wound dressings from your GP to help manage actively pus-producing 
lesions. Incontinence pads might be needed for high volume of discharge. 
• HS is not a disease of poor hygiene, however, using an antiseptic wash, such as 
chlorhexidine solution for the shower, available via the GP, may be beneficial. 
• There is no high-quality evidence that particular diets are helpful in HS.  
• If you are overweight, weight reduction may improve your disease severity and, 
depending on BMI, support from NHS weight-management services may be 
obtained. 
• Smoking is a risk factor for development of HS and people with HS have a relatively 
high risk of cardiovascular disease so stopping smoking, if you currently smoke, is an 
important part of self-management. 
• Depression is more common in those with HS and it is important to seek help from 
your GP for low mood, if relevant.  
 
8.0 RECOMMENDED AUDIT POINTS  
1. In the last 20 consecutive patients diagnosed with hidradenitis suppurativa is there 
evidence of: 
a) provision of a patient information leaflet 
b) an offer of smoking cessation referral, where relevant 
c) an offer of weight management referral, where relevant 
d) screening for co-morbidities: 
• depression 
• anxiety 
• cardiovascular risk factors (e.g. diabetes, hypertension, hyperlipidaemia 
and central obesity) 
e) documentation of baseline disease stage (mild, moderate, severe, based on 
Hurley system)  
f) documentation of disease severity using recognized instruments, including 
quality of life and pain  
g) a pre-operative discussion for those undergoing surgery, covering duration of 
recovery and wound care 
 
2. In the last 20 consecutive patients with hidradenitis suppurativa receiving 
adalimumab therapy: 
a) was a baseline count of inflammatory nodules, abscesses and draining sinus 
tracts performed? 
b) was there documentation of a Hurley score of II or III in at least one skin 
region? 
c) was there documentation of contraindication(s) or failure to respond to 
conventional systemic therapy?  
d) was treatment discontinued if there was a reduction of less than 25% in the 
baseline total abscess and inflammatory nodule count or any increase in 
abscesses or draining sinuses? 
 
The audit recommendation of 20 cases per department is to reduce variation in the results 
due to a single patient and allow benchmarking between different units. However, 
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departments unable to achieve this recommendation may choose to audit all cases seen in 
the preceding 12 months. 
 
9.0 STAKEHOLDER INVOLVEMENT AND PEER REVIEW 
The draft document and supporting information was made available to the BAD membership, 
British Dermatological Nursing Group (BDNG), Primary Care Dermatological Society 
(PCDS), British Society for Dermatological Surgery (BSDS), British Association of Plastic, 
Reconstructive & Aesthetic Surgeons (BAPRAS), British Medical Laser Association (BMLA), 
colorectal surgeons and a microbiologist for comments, which were actively considered by 
the GDG. Following further review, the finalized version was sent for peer-review by the 
Clinical Standards Unit of the BAD, made up of the Therapy & Guidelines Sub-committee 
(T&G), prior to submission for publication.  
 
10.0 LIMITATIONS OF THE GUIDELINE 
This document has been prepared on behalf of the BAD and is based on the best data 
available when the document was prepared. It is recognised that under certain conditions it 
may be necessary to deviate from the guidelines and that the results of future studies may 
require some of the recommendations herein to be changed. Failure to adhere to these 
guidelines should not necessarily be considered negligent, nor should adherence to these 
recommendations constitute a defence against a claim of negligence. 
 
11.0 PLANS FOR GUIDELINE REVISION 
The proposed revision date for this set of recommendations is scheduled for 2023; where 
necessary, important interim changes will be updated on the BAD website. 
 
SUPPORTING INFORMATION 
Additional supporting information, including the study selection PRISMA flow diagram, 
summary of findings with forest plots, GRADE evidence profiles indicating the quality of 
evidence, clinical evidence summary, summary of included studies, narrative findings for 
non-comparative studies, LETR, lists of excluded studies and search strategy may be found 
in the online version of this article. 
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